ovarian cancer screeningtransvaginal ultrasoundThe ability to detect ovarian cancer at preclinical or very early stages of development would confer a significant benefit in the therapeutic efficacy and overall survival associated with this devastating disease. The inadequate performance of currently used ...
Screening for Ovarian Cancer: An Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 157. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05231-EF-1. 4. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: an ...
The FDA has not approved or cleared screening tests for ovarian cancer, and in the past, has used "enforcement discretion" for LDTs. But the accessibility of lab-created tests has increased, prompting the agency to require labs to obtain a form of clearance, such as in the cases of 23andM...
The US Preventive Services Task Force (USPSTF) recommends against screening (with serum CA-125 level or transvaginal ultrasonography) for ovarian cancer in the general population.[3]The US Food & Drug Administration (FDA) recommends against the use of tests marketed for ovarian cancer screening.[4...
Screening ended on Dec 31, 2011, and included 345570 MMS and 327775 USS annual screening episodes. At a median follow-up of 11·1 years (IQR 10·0–12·0), we diagnosed ovarian cancer in 1282 (0·6%) women: 338 (0·7%) in the MMS group, 314 (0·6%) in the USS group, and ...
Ovarian cancer has a high case-fatality ratio, with most women not diagnosed until the disease is in its advanced stages. The United Kingdom Collaborative ... JT Thigpen - 《Yearbook of Medicine》 被引量: 896发表: 2009年 Ovarian cancer screening and mortality in the UK Collaborative Trial ...
To the Editor.—The study by Helzlsouer et al1concludes that CA-125 levels are not sensitive enough to screen for ovarian cancer. We believe that this test is an effective screening tool if used correctly.In their study, Helzlsouer et al1used a single CA-125 determination from 1974 as ...
is that women may have symptoms suggestive of ovarian cancer but then undergo this testing and it doesn't suggest ovarian cancer. They may then delay seeking medical intervention. In addition, there is the opposite concern: that unnecessary surgery could be performed in the case of a false [po...
To examine the impact of multimodal (MMS) and ultrasound (USS) screening on the sexual activity and functioning of 22 966 women in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) RCT. Methods: Fallowfield’s Sexual Activity Questionnaire (FSAQ) was completed prior to randomis...
New markers for use in screening Evaluation of markers Use of ovarian cancer screening in the at-risk population This work was supported by P50 CA83636 and RO1 CA96976 from the National Institutes of Health/National Cancer Institute. © 2003 Elsevier Inc. Tous droits réservés.Export...